ArticleJournal of virology2010
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Validation of Recombinant Type I Interferon Antiviral Activity Against Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.Veterinary sciences · 2026Article
- SIR+ models: accounting for interaction-dependent disease susceptibility in the planning of public health interventions.Scientific reports · 2024Article
- Oral Cavity Microbiome Impact on Respiratory Infections Among Children.Pediatric health, medicine and therapeutics · 2024Review
- New-age vaccine adjuvants, their development, and future perspective.Frontiers in immunology · 2023Review
- Article
- Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.Cell reports · 2022Article
- Dysbiosis in Pediatrics Is Associated with Respiratory Infections: Is There a Place for Bacterial-Derived Products?Microorganisms · 2021Review
- A new perspective for mitigation of SARS-CoV-2 infection: priming the innate immune system for viral attack.Open biology · 2020Article
- Inflammation and Cognition in Children and Adolescents: A Call for Action.Frontiers in pediatrics · 2020Article
- The Potential of Influenza HA-Specific Immunity in Mitigating Lethality of Postinfluenza Pneumococcal Infections.Vaccines · 2019Article
- LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice.Scientific reports · 2019Article
- Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.Frontiers in immunology · 2019Review
- Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.ILAR journal · 2018Review
- The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.mSphere · 2018Review
- Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations.Frontiers in immunology · 2018Review
- Impact of the Respiratory Microbiome on Host Responses to Respiratory Viral Infection.Vaccines · 2017Review
- Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model.Scientific reports · 2016Article
- Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.Immunology and cell biology · 2016Article
- Reducing the impact of influenza-associated secondary pneumococcal infections.Immunology and cell biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prophylactic or therapeutic immunomodulation is an antigen-independent strategy that induces nonspecific immune system activation, thereby enhancing host defense to disease. In this study, we investigated the effect of prophylactic immunomodulation on the outcome of influenza virus infection using three bacterially derived immune-enhancing agents known for promoting distinct immunological profiles. BALB/c mice were treated nasally with either cholera toxin (CT), a mutant form of the CT-related Escherichia coli heat-labile enterotoxin designated LT(R192G), or CpG oligodeoxynucleotide. Mice were subsequently challenged with a lethal dose of influenza A/PR/8/34 virus 24 h after the last immunomodulation treatment and either monitored for survival or sacrificed postchallenge for viral and immunological analysis. Treatment with the three immunomodulators prevented or delayed mortality and weight loss, but only CT and LT(R192G) significantly reduced initial lung viral loads as measured by plaque assay. Analysis performed 4 days postinfection indicated that prophylactic treatments with CT, LT(R192G), or CpG resulted in significantly increased numbers of CD4 T cells, B cells, and dendritic cells and altered costimulatory marker expression in the airways of infected mice, coinciding with reduced expression of pulmonary chemokines and the appearance of inducible bronchus-associated lymphoid tissue-like structures in the lungs. Collectively, these results suggest that, despite different immunomodulatory mechanisms, CT, LT(R192G), and CpG induce an initial inflammatory process and enhance the immune response to primary influenza virus challenge while preventing potentially damaging chemokine expression. These studies provide insight into the immunological parameters and immune modulation strategies that have the potential to enhance the nonspecific host response to influenza virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.